Climb Bio Past Earnings Performance
Past criteria checks 0/6
Climb Bio's earnings have been declining at an average annual rate of -8.8%, while the Biotechs industry saw earnings growing at 19% annually.
Key information
-8.8%
Earnings growth rate
54.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -28.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Revenue & Expenses Breakdown
How Climb Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -64 | 9 | 58 |
| 31 Mar 24 | 0 | -15 | 8 | 9 |
| 31 Dec 23 | 0 | -35 | 10 | 12 |
| 30 Sep 23 | 0 | -39 | 13 | 15 |
| 30 Jun 23 | 0 | -45 | 15 | 17 |
| 31 Mar 23 | 0 | -54 | 18 | 22 |
| 31 Dec 22 | 0 | -45 | 19 | 26 |
| 30 Sep 22 | 0 | -48 | 18 | 28 |
| 30 Jun 22 | 0 | -49 | 17 | 30 |
| 31 Mar 22 | 0 | -46 | 15 | 27 |
| 31 Dec 21 | 0 | -52 | 12 | 23 |
| 30 Sep 21 | 0 | -57 | 10 | 21 |
| 30 Jun 21 | 0 | -49 | 7 | 17 |
| 31 Mar 21 | 0 | -40 | 4 | 12 |
| 31 Dec 20 | 0 | -23 | 2 | 9 |
Quality Earnings: CLYM is currently unprofitable.
Growing Profit Margin: CLYM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLYM is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare CLYM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLYM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.6%).
Return on Equity
High ROE: CLYM has a negative Return on Equity (-28.88%), as it is currently unprofitable.